We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to Third Party Site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Guidelines and Recommendations

 

The below links to evidence-based clinical guidelines and recommendations provide guidance on the use of emicizumab in patients with hemophilia A.

National Bleeding Disorders Foundation Medical and Scientific Advisory Council (MASAC Document #268)

Recommendations on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors.

Link

National Bleeding Disorders Foundation Medical and Scientific Advisory Council (MASAC Document #267)

Recommendations on prophylaxis for hemophilia A and B with and without inhibitors.

Link

World Federation of Hemophilia Guidelines for the Management of Hemophilia, 3rd edition

Srivastava A, Santagostino E, Dougall  A, et al.  Haemophilia. 2020;26 Suppl 6:1-158.

Link